Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2013
February 2013, Vol 4, No 2
February 2013, Vol 4, No 2
Gene-Expression Profiling May Help Select Best Drugs for Pancreatic Cancer
By
Caroline Helwick
GI Cancers Symposium
February 2013, Vol 4, No 2
San Francisco, CA—Gene-expression profiling (GEP) of circulating tumor cells (CTCs) may help to personalize chemotherapy for patients with pancreatic cancer by predicting how patients will respond to certain treatments, according to a study reported at the 2013 Gastrointestinal Cancers Symposium.
Read Article
Ponatinib: New Option for the Treatment of Adults with CML or Ph+ ALL that Is Resistant or Intolerant to Previous Therapy with Tyrosine Kinase Inhibitors
By
Lynne Lederman, PhD, Medical Writer
Drug Updates
February 2013, Vol 4, No 2
On December 14, 2012, the US Food and Drug Administration (FDA) granted accelerated approval to ponatinib (Iclusig; ARIAD Pharmaceuticals) based on the results from a phase 2 clinical trial.
Read Article
Local Ablation Extends Therapy Duration for Patients with NSCLC, Improves Disease Control
By
Charles Bankhead
Lung Cancer
February 2013, Vol 4, No 2
Boston, MA—Patients with
ALK
-positive non–small-cell lung cancer (NSCLC) continued with crizotinib therapy more than twice as long when drug-resistant lesions were managed with local ablation, as shown by the results of a small clinical trial presented at the 2012 American Society for Radiation Oncology meeting.
Read Article
Real-World Evidence Shows Impact of Musculoskeletal Toxicity of Aromatase Inhibitors on Women with Breast Cancer
By
Phoebe Starr
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
February 2013, Vol 4, No 2
San Antonio, TX—Studies have suggested that musculoskeletal toxicity associated with aromatase inhibitor therapy can lead to noncompliance in up to 33% of women with breast cancer. A new, large cohort study at a single regional cancer center showed that the rate of musculoskeletal toxicity in women with early breast cancer who were treated with endocrine therapy was 64%.
Read Article
Drugs to Reduce Breast Cancer Risk Are Rarely Used Show Data from Geisinger Health System
By
Caroline Helwick
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
February 2013, Vol 4, No 2
San Antonio, TX—The uptake of US Food and Drug Administration (FDA)-approved drugs for risk reduction of breast cancer is still poor, as was confirmed by a study using the electronic health records (EHRs) from Geisinger Health System in Danville, PA.
Read Article
Second-Line Rituximab Maintenance for Follicular Lymphoma Cost-Effective
By
Caroline Helwick
ASH 2013 Annual Meeting
February 2013, Vol 4, No 2
Atlanta, GA—Dutch investigators found that rituximab (Rituxan) maintenance in the second-line treatment of patients with follicular lymphoma (FL) was cost-effective, as reported at the 2012 American Society of Hematology meeting.
Read Article
Ruxolitinib Treatment Reduces Myelofibrosis Symptoms, Spleen Size
By
Wayne Kuznar
ASH 2013 Annual Meeting
February 2013, Vol 4, No 2
Atlanta, GA—Ruxolitinib (Jakafi) alleviates symptoms such as fever, headache, weight loss, and fatigue, and reduces spleen size in patients with myelofibrosis.
Read Article
Is Fatherhood a Risk Factor for Prostate Cancer?
By
Rosemary Frei, MSc
Health Policy
,
Policies & Guidelines
February 2013, Vol 4, No 2
Socioeconomic status and other nonphysiologic factors may be largely responsible for the apparent association between having fathered a child and an increased risk for prostate cancer, Swedish researchers have concluded.
Read Article
Time to Review Practice Policies: HIPAA Privacy and Security Regulations Released
By
Ross D. Margulies, JD, MPH
;
Jayson Slotnik, JD, MPH
Health Policy
,
Policies & Guidelines
February 2013, Vol 4, No 2
On January 17, 2013, nearly 3 years after its initial proposed rule, the US Department of Health and Human Services (HHS) issued the long-awaited and much- anticipated HIPAA “omnibus” rule, extending the scope of the privacy law beyond providers to their business associates and subcontractors and adding increased penalties.
Read Article
Preventive Therapy Preserves Sexual Function after Radiotherapy for Patients with Prostate Cancer
By
Charles Bankhead
Prostate Cancer
February 2013, Vol 4, No 2
Boston, MA—Patients with prostate cancer reported significantly better sexual function for up to 2 years after radiation therapy when they took sildenafil (Viagra) on a daily basis during and after treatment, according to results of a placebo-controlled clinical trial.
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma